Rafael Holdings, Inc. (RFL) Investor Relations Documents

Rafael Holdings, Inc. (RFL) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2026-07-08. Read in-app with summaries. First-party data.

Presentation: Rafael Holdings (NYSE: RFL) is a clinical-stage biotech firm expecting Phase 3 topline data and an NDA submission for Trappsol Cyclo in NPC in 2H 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-08PresentationPresentation
2026-06-11Press releaseRafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
2026-06-11Press releaseRafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
2026-06-10Press releaseRafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trapp
2026-04-22Press releaseRafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 posit
2025-10-28Press releaseRafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Ala
2025-09-16Press releaseRafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub
2025-08-27Press releaseRafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inb
2024-11-06Press releaseRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
2024-06-14Press releaseRafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

RFL overview · RFL earnings · RFL financials · RFL KPIs · RFL ownership · RFL peers · RFL filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.